Performance of Abiraterone and enzalutamide in metastatic castration-resistant prostate cancer men: A head to head comparison based on a 2014-2017 French population study

Lucie-Marie Scailteux (1) , Boris Campillo-Gimenez (2) , Sandrine Kerbrat (1) , Fabien Despas (3) , Sebastien Vincendeau (4) , Frédéric Balusson (1) , André Happe (1) , Emmanuel Nowak (5) , Emmanuel Oger (1)

1 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins
2 LTSI - Laboratoire Traitement du Signal et de l'Image
3 LEASP - Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps
4 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
5 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest

Domaines: Ingénierie biomédicale

Lucie-Marie Scailteux, Boris Campillo-Gimenez, Sandrine Kerbrat, Fabien Despas, Sebastien Vincendeau, et al.. Performance of Abiraterone and enzalutamide in metastatic castration-resistant prostate cancer men: A head to head comparison based on a 2014-2017 French population study. Pharmacoepidemiology and Drug Safety, 2019, 28, pp.128-128. ⟨hal-02302411⟩